Clinical Trial Update: Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating nivolumab for relapsed or residual hematological malignancies following allogeneic stem cell transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematological Malignancy

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Melbourne Health | Conditions: Haematological Malignancy | Phase 2 | Status: UNKNOWN